The Association between Insurance Status and Survival in Metastatic Renal Cell Carcinoma in the United States
The Association between Insurance Status and Survival in Metastatic Renal Cell Carcinoma in the...
Read More
Kidney Cancer Journal
Systemic therapy for oligo-progressive, metastatic renal cell carcinoma (mRCC) treated with stereotactic radiosurgery (SBRT): to switch or not to switch?
Systemic therapy for oligo-progressive, metastatic renal cell carcinoma (mRCC) treated with...
Read More
Second-Line Treatment of Metastatic Renal Cell Carcinoma: Systematic Review and Network Meta-Analysis
Second-Line Treatment of Metastatic Renal Cell Carcinoma: Systematic Review and Network...
Read More
Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial
Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or...
Read More
Safety of Nivolumab in Patients With Clear Cell (CC) or Non-Clear Cell (NCC) Renal Cell Carcinoma (RCC): Results From the Phase IIIb/IV CheckMate 374 Study
Safety of Nivolumab in Patients With Clear Cell (CC) or Non-Clear Cell (NCC) Renal Cell Carcinoma...
Read MoreExercise & Wellness
Mark A. Moyad, MD, MPH
University of Michigan
Ann Arbor, Michigan